Research programme: cancer therapeutics - Abraxis BioScience

Drug Profile

Research programme: cancer therapeutics - Abraxis BioScience

Alternative Names: ABI-010; ABI-013; ABI-139; nab®-17AAG; nab®-ABI-139; nab®-CY196; NBT-010

Latest Information Update: 22 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abraxis BioScience
  • Developer Celgene Corporation
  • Class Albumins; Antisense oligonucleotides; Taxanes
  • Mechanism of Action Antisense RNA inhibitors; HSP90 heat-shock protein inhibitors; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 13 Jan 2014 ABI 010 (NBT 010) licensed to NantBioScience
  • 16 Oct 2010 Abraxis BioScience has been acquired by Celgene Corporation
  • 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top